Science Explorer Back to mapMap
Discussion
Researcher · Eisai (United Kingdom) · United Kingdom

Silvija Kraljevic

Silvija Kraljevic publishes mostly in Oncology, Pulmonary and Respiratory Medicine and Hepatology, on topics such as Hepatocellular Carcinoma Treatment and Prognosis, Lung Cancer Treatments and Mutations and Cancer Genomics and Diagnostics.

ORCID 0000-0002-6220-7168 OpenAlex
World rank
#1,994,361
of 7,710,434 ranked researchers
Rank in United Kingdom
#146,650
of 367,258
Works
30
Citations
6k
Citations per work
200.0
h-index
9
i10-index 8Top 65% in Oncology
Silvija Kraljevic

What does Silvija Kraljevic research?

Silvija Kraljevic's work is mostly in Medicine (59%), Biochemistry, Genetics and Molecular Biology (18%).

Health Sciences: 18 works · 59.0% of their workMedicine: 18 works · 59.0% of their workOncology: 6 works · 19.6% of their workPulmonary and Respiratory Medicine: 5 works · 17.9% of their workHepatology: 5 works · 16.1% of their workEpidemiology: 2 works · 5.4% of their workEverything else: 7 works · 23.2% of their workLife Sciences: 5 works · 17.8% of their workBiochemistry, Genetics and Molecular Biology: 5 works · 17.8% of their workCancer Research: 3 works · 10.7% of their workMolecular Biology: 2 works · 7.1% of their workTHEIR WORKSilvija Kraljevic30works
Life Sciences18%Health Sciences59%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1859.0%
  2. Everything else723.2%
    1. Biochemistry, Genetics and Molecular Biology517.8%
  1. 1Oncology20% of their works
  2. 2Pulmonary and Respiratory Medicine18% of their works
  3. 3Hepatology16% of their works
  4. 4Cancer Research11% of their works
  5. 5Molecular Biology7% of their works
  6. 6Epidemiology5% of their works

Research topics

Which keywords describe Silvija Kraljevic's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Hepatocellular Carcinoma, Liver Cancer, Chemotherapy, Biomarkers, ALK Inhibitors and EGFR Mutations.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Targeted Therapy133 topics
  2. Clinical Trials92 topics
  3. Hepatocellular Carcinoma81 topic
  4. Liver Cancer81 topic
  5. Chemotherapy72 topics
  6. Biomarkers62 topics
  7. ALK Inhibitors51 topic
  8. EGFR Mutations51 topic
  9. Cancer Genomics41 topic
  10. Genomic Profiles41 topic
  11. Mutational Signatures41 topic
  12. Small-Cell Lung Cancer41 topic
  13. Cetuximab31 topic
  14. KRAS Mutations31 topic
  15. Adaptive Designs21 topic
  16. FGF2121 topic
  17. False Discovery Rate21 topic
  18. Fibroblast Growth Factor21 topic
  19. HIF-121 topic
  20. Warburg Effect21 topic

Where does Silvija Kraljevic work?

Silvija Kraljevic's main affiliation in the publication record is Eisai (United Kingdom), United Kingdom.

How many publications and citations does Silvija Kraljevic have?

OpenAlex counts 30 works and 6,001 citations for Silvija Kraljevic, an h-index of 9, ranking #1,994,361 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Silvija Kraljevic. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.